Business Wire

One Peak Closes Third Fund at $1Bn Hard Cap to Back Fast-Growing B2B Software Companies Across Europe and Israel

6.12.2022 13:14:00 EET | Business Wire | Press release

Share

One Peak, a leading investor for growth stage B2B software companies in Europe and Israel, is excited to announce the closing of One Peak Growth III at its hard cap of $1 billion. The fund was significantly oversubscribed, demonstrating strong LP demand. Building on the success of One Peak’s first two funds, the closing of One Peak Growth III brings the firm’s total assets under management to c. $2 billion. The size of the new fund makes One Peak, founded by David Klein and Humbert de Liedekerke Beaufort, the largest fund in Europe dedicated to backing fast growing B2B software companies in the $15m-$100m investment range.

Accelerating Growth

Humbert de Liedekerke Beaufort, Co-founder and Managing Partner, said: “Growth equity is a significantly underrepresented asset class in Europe versus the US and China. There are many world class founders in Europe who need capital and support to win at global scale, and One Peak fills that gap for the best B2B software companies. With Fund III, we’ll continue to partner with the most ambitious founders and support them with our sector expertise, global network, and value creation platform to build enduring companies against the backdrop of today’s macroeconomic headwinds. $15-100m is our investment sweet spot, where we act as a catalyst to accelerate growth and help companies realize their full potential.”

Deep B2B Sector Expertise

Over the past 8 years, One Peak has built a concentrated portfolio of minority stakes in category leading software companies such as Cymulate, Deepki, DocPlanner, PandaDoc, Neo4j, and Spryker Systems. The One Peak team is an active partner to the founders it backs and supports them in building lasting, category-defining companies for the long term. This includes access to some of the best B2B software operators in the world through One Peak’s Value Creation Team which is comprised of experts in sales, marketing, partnerships, product, tech, and talent.

David Klein, Co-founder and Managing Partner, said: “We are ultimately in the business of investing in exceptional founders, and we work alongside them with the same passion and dedication as they do. Our value-add is significantly enhanced by our fully integrated Value Creation Team, particularly when it comes to hiring the best talent, accelerating top line growth, driving global expansion, and improving product and technology capabilities. This is a key differentiator for our portfolio companies in building generational companies. Last but not least, we are grateful to our founders and LPs from around the globe for their continued trust.”

One Peak’s relationship-driven approach is augmented by PULSE, One Peak’s proprietary sourcing and business intelligence software platform. PULSE integrates with a plethora of data sources and continuously surfaces the most promising opportunities for new investments and bolt-on acquisitions for One Peak’s portfolio companies.

Strong Blue Chip Investor Base

Commitments to One Peak Growth III came from a diverse group of investors from the US and Europe, including blue chip university endowments, foundations, public pensions plans, insurance companies, asset managers, fund of funds, and family offices.

Proskauer Rose LLP and Van Campen Liem served as fund counsel to One Peak Growth III.

— Ends —

About One Peak

One Peak is a leading growth equity investment firm with approx. $2 billion in assets under management that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise and access to its extensive network to exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. One Peak’s investments include Ardoq, Brightflag, Coople, Cymulate, DataGuard, Deepki, DocPlanner, Emnify, HighQ, Infermedica, Keepit, Lucca, Neo4j, Orgvue, PandaDoc, Paysend, Quentic, Spryker Systems, and many more. To learn more, visit www.onepeak.tech.

Founder testimonials

“From the early days of our relationship, One Peak worked collaboratively with us to identify growth initiatives with the biggest impact. They helped us with revenue optimization, international expansion, M&A and the recruitment of world class talent. Above all, we really value the open and direct communication and are grateful for their trust, hard work, dedication, and passion to help us realize our vision.”

Mariusz Gralewski, Founder & CEO, DocPlanner

“One Peak has been a true value-add partner to us since day 1. They really are one of those rare investors that can zoom in and zoom out, talk big picture strategy and nitty-gritty operational details, and add value on the go-to-market side as well as challenge our thinking on product. Plus they are driven, passionate, have great clarity of thought, and are simply nice people – we genuinely enjoy the great cultural fit with the One Peak team.”

Emil Eifrem, Founder and CEO, Neo4j

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Charlotte McCrum
charlotte@harper-gray.com
+44 7903 985834

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye